Ilyang Pharmaceutical’s Parkinson’s disease drug candidate ‘Supect’ stated in international SCI journal

Ilyang Pharmaceutical(CEO Dong-Yeon Kim) announced ‘Supect(generic name: radotinib),’ the 18^th Korean new drug candidate for the treatment of Parkinson’s disease, was approved to be published in ‘Human Molecular Genetics,’ an international SCI journal.

With the impact factor of 5.34, ‘Human Molecular Genetics(HMG)’ is a renowned international journal that is ranked in the top 16% in the world....